MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib

Br J Haematol. 2012 May;157(4):510-4. doi: 10.1111/j.1365-2141.2012.09042.x. Epub 2012 Feb 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / pharmacology
  • Benzenesulfonates / therapeutic use*
  • Cell Line, Tumor
  • Dasatinib
  • Down-Regulation / genetics
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Sorafenib
  • Thiazoles / pharmacology
  • Thiazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Pyridines
  • Pyrimidines
  • Thiazoles
  • Niacinamide
  • Sorafenib
  • Dasatinib